Wire
Biossil reaches $1B valuation in OpenAI-led round
Biossil, a Toronto biotech that uses AI to revive failed drug candidates, raised $153 million in an OpenAI Startup Fund-led round at a $1 billion valuation, BetaKit reports after confirming the terms with CEO Anthony Mouchantaf. The all-equity financing follows the $70 million the company disclosed when it exited stealth and will fund clinical-development capacity and more candidate acquisitions. Builders in scientific AI should file the round as a reminder that model value is only realized when capital also reaches wet-lab and clinical execution; the archive’s Enveda analysis of that clinical-capital gate tracks the same handoff.